

Anison

Specific Wart Therapy

Warts are the most common dermatological infection caused by a virus called 'human papillomavirus' (HPV). According to a report, ~14 million people in US alone become newly infected with HPV each year. Currently available wart treatments are ablative. Topical treatments on the market are inefficient, taking up to three months to be effective as they do not target the underlying cause, which is fighting the virus itself. In fact, none of the current methods of wart removal target the underlying HPV infection. Our research team at ÅAU has studied and identified an anti-HPV compound from an ancient medicinal plant. The compound isolated by us, which is the core of the targeted treatment of warts, have an unbeatable competitive advantage over the other commercial products as possessing anti-HPV activity directly targeting the root cause of warts which is the HPV infection itself. For the treatment of warts, we have developed the product as a topical gel/cream. We found that the gel/cream effectively removed both human and animal warts and there was no recurrence of the warts as the compounds in the cream effectively treated the underlying HPV infection.

SPARK VALUE: We are excited to be participating in the SPARK program and looking forward to expand our networks and find seasoned partners whose guidance can help us in commercializing our product. SPARK program will also enable us to get valuable feedback from experts at regulatory pathways & clinical trials that is required to develop the product. At the same time, we will also be benefitted from networking with fellow scientists.

Preethy Paul, PhD

Anison Project Manager

Preethy has more than 12 years of experience in HPV related research starting from her PhD. Additionally, she has worked in 2 Business Finland –TUTLI projects related to HPV therapy and been scouting investors for commercializing the technology.



Senthil Kumar Rajendran, PhD

Anison Product Manager

Senthil is a medicinal chemist with 11 years of postdoctoral experience in drug discovery and development. He is the key person in developing the product targeting HPV-associated diseases.

John Eriksson, PhD

Anison Team Leader

John is a Professor in Cell Biology at Abo Akademi University & Director of Turku Bioscience. He has a longstanding interest in tech transfer initiatives with several collaborative articles and patents regarding both nanoparticle-mediated drug delivery as well as bioactive compounds that could be used in cancer therapies and/or provoking the stress response.

